GSK and Save the Children form unique partnership to save the lives of one million children?Working together to accelerate the availability of two children?s medicines and establishing a joint R&D board to tackle causes of newborn and infant death.

The partnership will initially run two flagship programmes in Sub Saharan Africa ? Democratic Republic of Congo and Kenya

An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK ( and Save the Children. This unique collaboration will see the two organisations work together in a very different way, sharing expertise, resources, reach and influence to tackle some of the leading causes of childhood deaths.

Download the infographic:

Multimedia content:?

Amongst the key initiatives are the transformation of an antiseptic used in mouthwash into a life-saving product for new-borns and the roll-out of a powder-form of an antibiotic in child friendly doses to help fight pneumonia ? one of the main killers of children under five.

For the first time, Save the Children will be involved in helping GSK to research and develop medicines for children, with a seat on a new paediatric R&D board to accelerate progress on innovative life-saving interventions for under- fives, and to identify ways to ensure the widest possible access in the developing world. GSK will be able to leverage Save the Children?s child health expertise and on-the- ground experience to reach children in the most remote and marginalised communities with basic healthcare.

The GSK-Save the Children partnership will also focus on widening vaccine coverage to the poorest children, increasing investment in health workers, as well as developing a low-cost nutritional product to help combat child malnutrition.

Flagship programmes will run initially in Democratic Republic of Congo and Kenya. These will be closely monitored and the evidence on how to save children?s lives at scale will be used to replicate programmes in other countries within Sub-Saharan Africa, Asia and Latin America.

While good progress has been made in recent years, almost seven million children died in 2011 through lack of access to basic healthcare, vaccines or nutritious food. Through these and other initiatives, the partnership aims to help save the lives of one million children in the next five years.

Justin Forsyth, the Chief Executive of Save the Children said, ?This ground breaking partnership involves both organisations working in genuinely new ways to save the lives of a million children. In the past Save the Children may not have embarked on a collaboration with a pharmaceutical company like GSK. But we believe we can make huge gains for children if we harness the power of GSK?s innovation, research and global reach.?

Sir Andrew Witty, CEO of GSK said: ?A partnership of this scale gives us an opportunity to do something amazing ? to save the lives of one million children and to transform the lives of millions more. At GSK we are motivated by developing innovative life-saving medicines and getting them to the people that need them. By joining forces with Save the Children, we can amplify these efforts to create a new momentum for change and stop children dying from preventable diseases. I hope this partnership inspires GSK employees and sets a new standard for how companies and NGOs can work together towards a shared goal.?

Key features of the partnership are:

?????Reformulating the antiseptic chlorhexidine ? found in GSK?s Corsodyl mouth-wash ? for cleansing the umbilical cord stump of new-borns to prevent serious infection, a major cause of newborn death in poor countries. Studies from South Asia suggest this simple intervention could prevent up to 1 in 6 new-born deaths in low resource settings.

?????Seeking the accelerated registration and roll-out of a child-friendly antibiotic, used to treat pneumonia ? which currently kills 1.4 million under-fives, in countries with a high-incidence of the illness. This will be developed in dose packs suitable for small babies and young infants. GSK will also work with Save the Children to explore the reformulation of an alternative child-friendly version in places where access to water and milk is not easy.

????? Seeking to widen vaccination coverage to the hardest to reach communities: for example, through greater use of mobile technology solutions, sending SMS messages to remind parents to take up vaccination services and providing health workers and health facilities with smartphones to allow them to record and schedule vaccinations.

?????Researching a new affordable nutrition product combatting the scourge of malnutrition ? the underlying cause of one in three deaths in under-fives. A joint GSK-Save the Children project team in Kenya is investigating the development of a low-cost nutritional product for the poorest families.

?????Investing in healthcare workers in the poorest communities, building on an existing GSK-Save the Children collaboration to help address the estimated shortfall of at least 3.5 million trained healthcare workers, who can deliver vaccines and essential medicines to babies and young children, provide health advice and treat malnutrition.

?????Building flagship country programmes initially in Democratic Republic of Congo (DRC) and Kenya to include these interventions, which will be closely monitored and evaluated to determine how the partnership is saving lives before scale-up and replication of the programmes in other developing countries.

?????Developing a blueprint for how businesses can deliver better social outcomes by engaging with health and development issues and pursuing joint advocacy efforts to ensure a focus on children?s health and wellbeing are maintained in global health policy discussions.

?????Inspiring and engaging GSK?s global workforce to help raise awareness through volunteering and fundraising, with the ambition to encourage employees to raise ?1 million a year, which will be matched by GSK.Through this and other charitable donations to Save the Children, GSK has committed to donate at least ?15 million over the course of the partnership. Additional contributions will be made through specific research and development programmes.

Save the Children and GSK have been working together for eight years on a number of public health projects, including GSK?s initiative to reinvest 20% of the profits it makes in least-developed-countries in community programmes to strengthen healthcare infrastructure, primarily through the training of community health workers.

Distributed by the African Press Organization on behalf of GlaxoSmithKline (GSK).

GlaxoSmithKline ( ? one of the world?s leading research-based pharmaceutical and healthcare companies ? is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit

Save the Children ? Save the Children works in more than 120 countries and helps to save children?s lives, fight for their rights and help them fulfil their potential. For more information visit:

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley????+44 (0) 20 8047 5502????(London)

David Daley????+44 (0) 20 8047 5502????(London)

Catherine Hartley????+44 (0) 20 8047 5502????(London)

Sarah Hornby????+44 (0) 20 8047 5502????(London)

US Media enquiries:

Stephen Rea????+1 215 751 4394????(Philadelphia)

Melinda Stubbee????+1 919 483 2510????(North Carolina)

Mary Anne Rhyne????+1 919 483 0492????(North Carolina)

Analyst/Investor enquiries:

Ziba Shamsi????+ 44 (0) 20 8047 3289????(London)

Lucy Budd????+44 (0) 20 8047 2248????(London)

Tom Curry????+ 1 215 751 5419????(Philadelphia)

Gary Davies????+ 44 (0) 20 8047 5503????(London)

James Dodwell????+ 44 (0) 20 8047 2406????(London)

Jeff McLaughlin????+ 1 215 751 7002????(Philadelphia)

Save the Children Enquiries:

Media enquiries:

Jo Campbell????+44 (0) 20 7012 6841????(London)

[email protected]

Emily Sharman????+44 (0) 20 7012 6841????(London)

[email protected]

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK? s operations are described under Item 3.D ?Risk factors? in the company?s Annual Report on Form 20-F for 2012.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex



GlaxoSmithKline (GSK)

Disclaimer: News Ghana is not responsible for the reportage or opinions of contributors published on the website.

Send your news stories to [email protected] and via WhatsApp on +1-508-812-0505 


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.